Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON A BERNER

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1144201781
CMS profile
97355
Location
JASPER, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$28,667.77

238 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 5 of 5; records 201–238 of 238 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON A BERNER

NPI 1144201781 · CMS profile ID 97355

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

JASPER, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–238 of 238 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144201781?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON A BERNER, NPI 1144201781, CMS profile ID 97355. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–238 of 238 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144201781?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JASON A BERNER, NPI 1144201781, CMS profile ID 97355. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–238 of 238 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144201781?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JASON A BERNER, NPI 1144201781, CMS profile ID 97355, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–238 of 238 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144201781?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

238 matching records · $28,667.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 238 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–238 of 238.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
MannKind Corporation $9.4002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821048445 CMS
SANOFI-AVENTIS U.S. LLC $22.2002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526303 CMS
RECORDATI_RARE_DISEASES_INC. $16.2702/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 831402077 CMS
Antares Pharma, Inc. $14.9002/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827486581 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3502/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763349966 CMS
Lilly USA, LLC $650.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818575171 CMS
Abbott Laboratories $562.5002/15/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818415063 CMS
Abbott Laboratories $562.5002/15/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818415065 CMS
Lilly USA, LLC $650.0002/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560789 CMS
Lilly USA, LLC $18.7602/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818575167 CMS
Corcept Therapeutics $21.0102/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837515917 CMS
Currax Pharmaceuticals LLC $16.2002/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792526037 CMS
Lilly USA, LLC $16.1602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819141667 CMS
MannKind Corporation $8.9602/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821048433 CMS
MannKind Corporation $8.9602/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821048437 CMS
Novo Nordisk Inc $10.4602/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810986015 CMS
SANOFI-AVENTIS U.S. LLC $9.9802/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526297 CMS
Lilly USA, LLC $18.3101/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560781 CMS
Lilly USA, LLC $650.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560785 CMS
Merck Sharp & Dohme Corporation $11.0901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848509321 CMS
Lilly USA, LLC $325.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818552075 CMS
Lilly USA, LLC $650.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819141655 CMS
Abbott Laboratories $21.2701/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818402415 CMS
Lilly USA, LLC $650.0001/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560787 CMS
Novo Nordisk Inc $12.2401/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810986007 CMS
AbbVie Inc. $11.2501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794050489 CMS
Lilly USA, LLC $19.9601/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560209 CMS
Lilly USA, LLC $17.9501/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560211 CMS
Lilly USA, LLC $1.7901/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819141659 CMS
AstraZeneca Pharmaceuticals LP $35.5601/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829950973 CMS
Zealand Pharma US, Inc. $12.5001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800225065 CMS
Antares Pharma, Inc. $17.0601/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827486579 CMS
Merck Sharp & Dohme Corporation $19.4801/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848442029 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2701/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763349968 CMS
Lilly USA, LLC $13.5301/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560783 CMS
Corcept Therapeutics $15.7401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837515915 CMS
Abbott Laboratories $13.3001/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818391005 CMS
Corcept Therapeutics $23.3401/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837515913 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $171,246.39 510
PY2020 $65,389.23 300
PY2021 $28,667.77 238
PY2022 $73,570.59 301
PY2023 $47,051.50 197
PY2024 $47,118.33 185
PY2025 $24,062.72 119

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $411,711.28 45
PY2024 Recipient $1,800.81 12
PY2024 Principal investigator $670,439.10 99
PY2023 Recipient $6,482.10 1
PY2023 Principal investigator $796,146.21 188
PY2022 Recipient $19,504.00 2
PY2022 Principal investigator $277,307.96 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533703
Principal investigator 1 ABBVIE INC. $4,130.00 11/05/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521751
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,790.00 10/15/2025 Non-covered Recipient Entity
ECIR MEDICAL COMMUNICATIONS
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185553759
Principal investigator 1 ABBVIE INC. $1,960.00 10/09/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514941
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,790.00 09/24/2025 Non-covered Recipient Entity
ECIR MEDICAL COMMUNICATIONS
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185553763
Principal investigator 1 ABBVIE INC. $14,672.00 09/04/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508434
Principal investigator 1 Alnylam Pharmaceuticals Inc. $244.00 08/13/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513588
Principal investigator 1 Alnylam Pharmaceuticals Inc. $416.00 08/13/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $324.00 08/13/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513597
Principal investigator 1 ABBVIE INC. $27,647.90 08/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502717
Principal investigator 1 Amgen Inc. $9,778.65 07/28/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640999
Principal investigator 1 AstraZeneca UK Limited $35,310.00 07/16/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185553761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,037.00 07/14/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,499.00 07/14/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 07/14/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513572
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/14/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513578
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,037.00 07/14/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215513601
Principal investigator 1 Amgen Inc. $47,172.15 07/08/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246641019
Principal investigator 1 ABBVIE INC. $17,921.40 07/02/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495763
Principal investigator 1 ABBVIE INC. $1,500.00 06/17/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202491803
Principal investigator 1 ABBVIE INC. $3,500.00 06/12/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202491227
Principal investigator 1 ABBVIE INC. $38,287.20 06/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488803
Principal investigator 1 Medtronic, Inc. $3,500.00 05/29/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323645
Principal investigator 1 ABBVIE INC. $5,934.60 05/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484001
Principal investigator 1 Ascendis Pharma Endocrinology Inc $463.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995381
Principal investigator 1 Ascendis Pharma Endocrinology Inc $369.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995435
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995451
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995453
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995455
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995457
Principal investigator 1 Ascendis Pharma Endocrinology Inc $263.00 04/11/2025 Non-covered Recipient Entity
Georgia Mountain Endocrinology, Corp
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995459
Principal investigator 1 ABBVIE INC. $19,124.00 04/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471030
Principal investigator 1 Medtronic, Inc. $729.75 04/03/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323641
Principal investigator 1 Medtronic, Inc. $103.25 04/03/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323643
Principal investigator 1 ABBVIE INC. $14,700.00 03/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461861
Principal investigator 1 Eli Lilly and Company $752.50 02/25/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187881382
Principal investigator 1 Medtronic, Inc. $550.00 02/13/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323635
Principal investigator 1 Medtronic, Inc. $375.00 02/13/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323637
Principal investigator 1 Medtronic, Inc. $500.00 02/13/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323639
Principal investigator 1 ABBVIE INC. $10,850.00 02/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448932
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,903.88 01/27/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH CANTON
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311309
Principal investigator 1 Eli Lilly and Company $73,812.00 01/21/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878881
Principal investigator 1 ABBVIE INC. $2,190.00 01/13/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202438151
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,304.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190300177
Principal investigator 1 ABBVIE INC. $3,304.00 01/02/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202435341